Lilly is racing to cement its leadership by developing new injectables and expanding into oralsthe pharmas next generation oral GLP-1 agonist orforglipron recently showed injectable-like effects in a Phase III trialbut faces a potential threat from investigational therapies that are dosed less frequently
Post hoc comparisons revealed a significant increase in appetite scores in the control group from pre- to post-alcohol administration (B = 23.27, t(18) = 5.0, p = 0.0005), while the GLP-1RA group showed no statistically significant change (B = 7.30, t(18) = 1.57, p = 0.41), however the GLP-1 group started with a slightly, but not significantly, higher baseline
S3 1 H NMR spectra of a 3-PLG-dopa, b 3-PLG-ibu, c 3-PLG-dopa-A-GSH, and d 3-PLG-ibu-A-GSH
The battle continues
Patients using GLP-1 receptor agonists were also more likely to have microvascular complications and a history of depression
Fix: Gentle swirling or rolling only